Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Receivables: 2017-2025

Historic Change in Receivables for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to -$6.2 million.

  • Akebia Therapeutics' Change in Receivables fell 356.13% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year increase of 279.14%. This contributed to the annual value of -$4.0 million for FY2024, which is 307.04% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Change in Receivables is -$6.2 million, which was down 153.44% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Change in Receivables ranged from a high of $27.9 million in Q1 2025 and a low of -$58.7 million during Q3 2022.
  • For the 3-year period, Akebia Therapeutics' Change in Receivables averaged around $2.6 million, with its median value being $3.0 million (2023).
  • Over the last 5 years, Akebia Therapeutics' Change in Receivables had its largest YoY gain of 7,399.56% in 2022, and its largest YoY loss of 499.95% in 2022.
  • Akebia Therapeutics' Change in Receivables (Quarterly) stood at $1.2 million in 2021, then skyrocketed by 1,329.83% to $17.0 million in 2022, then fell by 1.86% to $16.7 million in 2023, then tumbled by 81.59% to $3.1 million in 2024, then slumped by 356.13% to -$6.2 million in 2025.
  • Its Change in Receivables stands at -$6.2 million for Q3 2025, versus $11.5 million for Q2 2025 and $27.9 million for Q1 2025.